Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RHT We View Red Hat’s Stock As Reasonably Priced, Says UBS; Reduces PT To $68 http://www.smarteranalyst.com/2014/09/19/58211/
$RHT We View Red Hat’s Stock As Reasonably Priced, Says UBS; Reduces PT To $68 http://www.smarteranalyst.com/2014/09/19/58211/
$AUXL Auxilium: We Are Moving To The Sidelines, Says UBS http://www.smarteranalyst.com/2014/09/19/auxilium-moving-sidelines-says-ubs/
$AUXL Auxilium: We Are Moving To The Sidelines, Says UBS http://www.smarteranalyst.com/2014/09/19/auxilium-moving-sidelines-says-ubs/
SLB We Remain Very Positive On Schlumberger’s Outlook Despite Estimate Cuts, Says Griffin
http://www.smarteranalyst.com/2014/09/19/remain-positive-schlumbergers-outlook-despite-estimate-cuts-says-griffin/
$SYN Maxim Remains Positive On Synthetic Biologics Following R&D Day http://www.smarteranalyst.com/2014/09/19/maxim-remains-positive-on-synthetic-biologics-following-rd-day/
$SPPI $CASI Roth Capital Reiterates Buy On Spectrum On The Back Of License Agreement With CASI http://www.smarteranalyst.com/2014/09/19/roth-capital-reiterates-buy-spectrum-back-license-agreement-casi/
Roth Capital Reiterates Buy On Spectrum On The Back Of License Agreement With CASI http://www.smarteranalyst.com/2014/09/19/roth-capital-reiterates-buy-spectrum-back-license-agreement-casi/
$RNA Roth Capital Sees 93% Upside In Prosensa But Financial Overhang Still Exist http://www.smarteranalyst.com/2014/09/19/roth-capital-sees-93-upside-prosensa-financial-overhang-still-exist/
$RNA Roth Capital Sees 93% Upside In Prosensa But Financial Overhang Still Exist http://www.smarteranalyst.com/2014/09/19/roth-capital-sees-93-upside-prosensa-financial-overhang-still-exist/
$SNGX Brean Capital Maintains Buy On Soligenix Following NIAID Contract Award http://www.smarteranalyst.com/2014/09/19/brean-capital-maintains-buy-soligenix-following-niaid-contract-award/
Cantor Raises Yahoo! Price Target To $43 On The Heels Of Alibaba’s IPO
http://www.smarteranalyst.com/2014/09/19/cantor-raises-yahoo-price-target-43-heels-alibabas-ipo/
Cantor Raises Yahoo! Price Target To $43 On The Heels Of Alibaba’s IPO
http://www.smarteranalyst.com/2014/09/19/cantor-raises-yahoo-price-target-43-heels-alibabas-ipo/
$BABA Ahead Of Alibaba’s IPO: Cantor Initiates Buy, Sets $90 Price Target
http://www.smarteranalyst.com/2014/09/19/ahead-alibabas-ipo-cantor-initiates-buy-sets-90-price-target/
Ahead Of Alibaba’s IPO: Cantor Initiates Buy, Sets $90 Price Target http://www.smarteranalyst.com/2014/09/19/ahead-alibabas-ipo-cantor-initiates-buy-sets-90-price-target/
We Recommend That Investors Accumulate Shares Of Activision Blizzard, Says Wedbush http://www.smarteranalyst.com/2014/09/18/recommend-investors-accumulate-shares-activision-blizzard-says-wedbush/
$UNFI UBS Slightly Cuts United Natural Foods PT To $68 Following Earnings http://www.smarteranalyst.com/2014/09/18/ubs-slightly-cuts-united-natural-foods-pt-68-following-earnings/
$UNFI UBS Slightly Cuts United Natural Foods PT To $68 Following Earnings http://www.smarteranalyst.com/2014/09/18/ubs-slightly-cuts-united-natural-foods-pt-68-following-earnings/
$EGRX Cantor Fitzgerald Reiterates Sell On Endo Health, Increases PT To $56
http://www.smarteranalyst.com/2014/09/18/cantor-fitzgerald-maintains-buy-eagle-pharma-teva-removes-initial-lawsuit-files-another-one/
$ENDP Cantor Fitzgerald Reiterates Sell On Endo Health, Increases PT To $56
http://www.smarteranalyst.com/2014/09/18/cantor-fitzgerald-reiterates-sell-endo-health-increases-pt-56/
$ENDP Cantor Fitzgerald Reiterates Sell On Endo Health, Increases PT To $56 http://www.smarteranalyst.com/2014/09/18/cantor-fitzgerald-reiterates-sell-endo-health-increases-pt-56/
$BBSI Roth Capital Comments On BBSI Following An Update Call With Management http://www.smarteranalyst.com/2014/09/18/roth-capital-comments-bbsi-following-update-call-management/
$BLRX Biolinerx: Strong Preclinical Support And Prepping for Important Clinical Data, Says Roth Capital http://www.smarteranalyst.com/2014/09/18/biolinerx-strong-preclinical-support-prepping-important-clinical-data-says-roth-capital/
$BLRX Biolinerx: Strong Preclinical Support And Prepping for Important Clinical Data, Says Roth Capital http://www.smarteranalyst.com/2014/09/18/biolinerx-strong-preclinical-support-prepping-important-clinical-data-says-roth-capital/
$CALD Callidus: Shares Attractively Valued On Sharp Pullback, Says Roth Capital http://www.smarteranalyst.com/2014/09/18/callidus-shares-attractively-valued-sharp-pullback-says-roth-capital/
$CALD Callidus: Shares Attractively Valued On Sharp Pullback, Says Roth Capital http://www.smarteranalyst.com/2014/09/18/callidus-shares-attractively-valued-sharp-pullback-says-roth-capital/
$CNCE $CELG Roth Capital Reiterates Buy On Concert Following Initiation Of Phase I Study http://www.smarteranalyst.com/2014/09/18/roth-capital-reiterates-buy-concert-following-initiation-phase-study/
$CNCE $CELG Roth Capital Reiterates Buy On Concert Following Initiation Of Phase I Study http://www.smarteranalyst.com/2014/09/18/roth-capital-reiterates-buy-concert-following-initiation-phase-study/
$CTIC: Licensing Deal With Servier Incrementally Positive, Says Roth Capital http://www.smarteranalyst.com/2014/09/18/ctic-licensing-deal-servier-incrementally-positive-says-roth-capital/
$ORPN Roth Capital Maintains Buy On Bio Blast Following Preclinical Data Release http://www.smarteranalyst.com/2014/09/18/roth-capital-maintains-buy-bio-blast-following-preclinical-data/
$RPRX Brean Capital Maintains Bullish Stance On Repros, $41 PT http://www.smarteranalyst.com/2014/09/18/brean-capital-maintains-bullish-stance-repros-41-pt/
$BA Canaccord Maintains Buy On Boeing Following New $4.2B Contract From NASA For Next Passenger Spacecraft http://www.smarteranalyst.com/2014/09/17/canaccord-maintains-buy-on-boeing-following-new-4-2b-contract-from-nasa-for-next-passenger-spacecraft/
$SSNI Canaccord Maintains Hold On Silver Spring, Sees 20% Upside For The Stock http://www.smarteranalyst.com/2014/09/17/canaccord-maintains-hold-on-silver-spring-sees-19-9-upside-for-the-stock/
$SSNI Canaccord Maintains Hold On Silver Spring, Sees 20% Upside For The Stock http://www.smarteranalyst.com/2014/09/17/canaccord-maintains-hold-on-silver-spring-sees-19-9-upside-for-the-stock/
$SNGX Maxim Maintains Buy On Soligenix Following Preclinical Results http://www.smarteranalyst.com/2014/09/17/maxim-maintains-buy-on-soligenix-following-preclinical-results/
$BLRX Maxim Group Maintains Buy On Biolinerx Following Presentation At The SOHO http://www.smarteranalyst.com/2014/09/17/maxim-group-maintains-buy-on-biolinerx-following-presentation-at-the-soho/
$RAX Rackspace Shares Are Attractively, Says William Blair; Reiterates Outperform http://www.smarteranalyst.com/2014/09/17/rackspace-shares-are-attractively-says-william-blair-reiterates-outperform/
$RAX Rackspace Shares Are Attractively, Says William Blair; Reiterates Outperform http://www.smarteranalyst.com/2014/09/17/rackspace-shares-are-attractively-says-william-blair-reiterates-outperform/
$GNC William Blair Remains Bearish On GNC Holdings Shares http://www.smarteranalyst.com/2014/09/17/william-blair-remains-bearish-on-gnc-holdings-shares/
$ENDP William Blair Comments On Endo Following Proposal To Acquire Auxilium http://www.smarteranalyst.com/2014/09/17/william-blair-comments-on-endo-following-proposal-to-acquire-auxilium/